



## IOL CHEMICALS AND PHARMACEUTICALS LIMITED

IOLCP/CGC/2016  
08 August 2016

The General Manager  
**National Stock Exchange of India Ltd.**  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051

The General Manager  
**BSE Limited.**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai

**Subject: Disclosure under Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir,

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on 08 August 2016 had approved the Un-audited Financial Results of the Company for the quarter ended 30 June 2016. In this regard, please find enclosed herewith the following:

1. Un-audited Financial Results for the quarter ended 30 June 2016
2. Independent Auditors' Review Report on the Un-audited Financial Results for the Quarter ended 30 June 2016
3. Press Release for the results.

Kindly note that the meeting of Board of Directors commenced at 12:00 noon and concluded at 04:15 p.m.

Thanking you

Yours faithfully,  
for IOL Chemicals and Pharmaceuticals Limited

  
[Krishan Singla]  
Vice President & Company Secretary

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030  
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com  
Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India  
Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.  
Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2016

Rs. in Lacs

Sr. No.	Particulars	Quarter Ended		Year ended	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		30.06.2016	31.03.2016	30.06.2015	31.03.2016
1	<b>Income from Operations</b>				
a	Net Sales / Income from operations (net of excise duty)	16198.31	14218.21	13694.42	58041.53
b	Other Operating Income	26.83	28.58	28.47	120.96
	<b>Total income from Operations (net)</b>	<b>16225.14</b>	<b>14246.79</b>	<b>13722.89</b>	<b>58162.49</b>
2	<b>Expenses</b>				
a	Cost of materials consumed	10751.97	9553.43	10499.87	43480.00
b	Purchase of stock-in-trade	0.00	0.00	0.00	0.00
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(78.16)	(510.68)	(3.14)	(2119.56)
d	Employee benefits expense	1096.00	1031.99	787.90	3512.71
e	Depreciation and amortisation expense	748.02	739.20	737.11	2968.64
f	Other expenditure	1886.31	1661.22	2223.79	8030.94
	<b>Total Expenses</b>	<b>14404.14</b>	<b>12475.16</b>	<b>14245.53</b>	<b>55872.73</b>
3	Profit from Operations before Other Income, finance cost and Exceptional Items ( 1-2 )	1821.00	1771.63	(522.64)	2289.76
4	Other Income	0.45	0.45	0.45	1.80
5	Profit from ordinary activities before finance cost and exceptional items (3+4)	1821.45	1772.08	(522.19)	2291.56
6	Finance costs	1717.41	1612.95	1453.74	6146.60
7	Profit from ordinary activities after finance costs but before exceptional items (5-6)	104.04	159.13	(1975.93)	(3855.04)
8	Exceptional Items	0.00	0.00	0.00	0.00
9	<b>Profit (+) / Loss (-) from ordinary activities before tax (7+8)</b>	<b>104.04</b>	<b>159.13</b>	<b>(1975.93)</b>	<b>(3855.04)</b>
10	Tax Expense	31.25	46.47	(181.75)	147.56
11	<b>Net Profit (+)/Loss (-) from ordinary activities after tax (9-10)</b>	<b>72.79</b>	<b>112.66</b>	<b>(1794.18)</b>	<b>(4002.60)</b>
12	Extraordinary Item (net of tax expense)				
13	Net Profit (+)/Loss (-) for the period (11-12)	72.79	112.66	(1794.18)	(4002.60)
14	Paid-up equity share capital (Face value Rs.10/- Per Share)	5620.55	5620.55	4995.55	5620.55
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				12892.37
16	Earning per share (before and after extraordinary item (Face value of Rs. 10/- each)				
	Basic (Weighted)	0.13	0.20	(3.72)	(7.60)
	Diluted (Weighted)	0.13	0.20	(3.44)	(7.60)
	Cash (Weighted)	1.48	1.60	(2.57)	(1.68)



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030  
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com  
 Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India  
 Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.  
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



# IOL CHEMICALS AND PHARMACEUTICALS LIMITED

Segment wise Revenue, Results and Capital Employed, along with the quarterly results


Rs. in Lacs

Particulars	Quarter ended			Year Ended
	Unaudited 30.06.2016	Audited 31.03.2016	Unaudited 30.06.2015	Audited 31.03.2016
<b>1. Segment Revenue</b> (Net sale/income)				
- Chemicals	9946.06	8890.16	8369.25	35596.38
- Drugs	8487.26	6913.46	7552.68	30798.96
- Unallocated	73.58	57.44	41.16	266.78
<b>Total</b>	<b>18506.90</b>	<b>15861.06</b>	<b>15963.09</b>	<b>66662.12</b>
Less : Inter segment revenue	2281.76	1614.27	2240.20	8499.63
<b>Net sales/income from operations</b>	<b>16225.14</b>	<b>14246.79</b>	<b>13722.89</b>	<b>58162.49</b>
<b>2. Segment Results</b>				
<b>Profit(+)/(loss)(-) before tax and interest</b> from each segment)				
- Chemicals	(176.39)	(56.19)	(1712.72)	(4150.06)
- Drugs	1996.37	1785.68	1184.51	6210.95
<b>Total</b>	<b>1819.98</b>	<b>1729.49</b>	<b>(528.21)</b>	<b>2060.89</b>
Less: Interest	1717.41	1612.95	1453.74	6146.60
Less: Other un-allocable expenditure net of unallocable income	(1.47)	(42.59)	(6.02)	(230.67)
<b>Total Profit(+)/(loss) (-) before tax &amp; Extraordinary items</b>	<b>104.04</b>	<b>159.13</b>	<b>(1975.93)</b>	<b>(3855.04)</b>
<b>3. Capital Employed</b> (Segment assets - Segment Liabilities)				
- Chemicals	1717.26	2445.50	5082.23	2445.50
- Drugs	15299.06	14759.78	13151.68	14759.78
- Unallocated	1569.41	1307.64	1174.92	1307.64
<b>Total</b>	<b>18585.73</b>	<b>18512.92</b>	<b>19408.83</b>	<b>18512.92</b>

**NOTES:**

1. The above results have been reviewed by the Audit & Risk Management Committee and were considered and approved by the Board of Directors at their meeting held on 08 August 2016.
2. Limited review of the above unaudited financial results of the Company in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the Statutory Auditors of the Company.
3. Previous period's figures have been regrouped/ reclassified wherever necessary.

By order of the Board  
For IOL Chemicals and Pharmaceuticals Limited



*Vijay*  
Vijay Kumar Garg  
Joint Managing Director  
DIN: 06510248

Place: Ludhiana  
Date: 08 August 2016

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030  
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com  
Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India  
Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.  
Ph. : +91-1679 -285285-86, Fax : +91-1679-285292

**INDEPENDENT AUDITOR'S REVIEW REPORT**

To  
**The Board of Directors,  
IOL Chemicals and Pharmaceuticals Limited  
Ludhiana**

**Introduction**

We have reviewed the accompanying statement of standalone unaudited financial results of IOL Chemicals and Pharmaceuticals Limited (the Company) for the quarter ended 30<sup>th</sup> June, 2016. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

**Scope of Review**

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed any audit and, accordingly, we do not express an audit opinion.


**Conclusion**

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ludhiana  
Date: 08<sup>th</sup> August, 2016



For S.C. Vasudeva & Co.  
Chartered Accountants  
FRN- 000235N

  
(Sanjiv Mohan)  
Partner  
M. No. 086066



**IOL CHEMICALS AND PHARMACEUTICALS LIMITED**

*For immediate release*

Press Release

# **Impressive Results by IOL Chemicals and Pharmaceuticals Limited**

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of bulk drugs and specialty chemicals posted an impressive performance for the quarter ended 30 June 2016.

Net sales revenue increased by 18% during the quarter ended 30 June 2016 to Rs. 161.98 crore from Rs. 136.94 crore during the corresponding quarter of the previous year.

The company has earned profit after tax during the quarter ended 30 June 2016 of Rs. 0.73 crore against loss of Rs. 17.94 crore during the corresponding quarter of the previous year. The operating profit (EBITDA) for the quarter ended 30 June 2016 went up to Rs. 25.69 crore as against operating profit (EBITDA) of Rs. 2.14 crore reported in the corresponding quarter ended 30 June 2015.

The Ibuprofen manufacturing facilities have been approved by US Food and Drug Administration (USFDA), EDQM and WHO. The Company is already exporting its Ibuprofen in regulated & Emerging markets i.e. Europe, Latin America, Middle East, etc and with the recent approval from USFDA, the company is exploring its business in USA.

The company is in process of adding new pharma products in near future, which will add value to existing portfolio.

## **About IOL Chemicals and Pharmaceuticals Limited (IOLCP)**

Company was established in 1986, listed on Bombay Stock Exchange (Code: 524164) and National Stock Exchange (Code: IOLCP) is India's one of the leading generic pharmaceutical company, and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, Anti-diabetic, Anti hypertensive, Anti Convulsants, etc.

IOLCP's product portfolio includes APIs; Ibuprofen, specialty chemicals such as Iso Butyl Benzene (IBB), Ethyl Acetate, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is world's only largest backward integrated Ibuprofen producer with an installed capacity of 6200TPA, manufacturing all intermediates stages and Key Starting Materials at one location. The company has DSIR approved R&D, which is fully equipped to validate existing processes. State of art Multipurpose plant provides significant upside opportunity for further development of APIs.

The Central and State Government approved Effluent Treatment Plant (ETP) was set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance.

IOLCP's overseas customers are spread out across several countries including Brazil, Argentina, China, Hungary, USA, Chile, Peru, Colombia, South Africa, Thailand, Australia, Netherlands, Iran and many other Middle East Countries. Products are sold primarily to Branded Generic formulators both in India & Overseas.

The Company is an - ISO 9001:2008, ISO 14001:2004 and OHSAS 18001:2007

For more information on IOLCP, please visit <http://www.iolcp.com>